AzTrials
AzTrials

Inguinal HerniaPhase 3NCT02634255

The Onset Time of Rocuronium in Emergency and Elective Surgery

A Phase 3 study testing Rocuronium elective surgery, Rocuronium emergency surgery and Propofol in people with Inguinal Hernia and Acute Appendicitis, run by Diskapi Yildirim Beyazit Education and Research Hospital.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Rocuronium, a nondepolarizing neuromuscular blocking agent, is used in general anesthesia to provide conditions for endotracheal intubating. Recommended dose is 0,6 mg/kg and 90 seconds after intravenous injection, patients can be intubated. Read more about this study

Who is it for?
Ages 18 to 65 years
Conditions the study is for
Inguinal Hernia, Acute Appendicitis
What is being tested?
Rocuronium elective surgery, Rocuronium emergency surgery and Propofol
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
50 participants
Where
No sites listed yet
Study dates
Dec 2015to Jul 2016
Phase
Phase 3
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • BMI 18,5-24,9
  • ASA 1

Who cannot join

  • Allergy to used drugs during anesthesia
  • Neuromuscular disease
  • Liver and kidney failure
  • Heart failure
  • Anticipated difficult airway
  • Using aminoglycosides
  • BMI<18,5 and BMI>25

Trial locations and contacts

No sites are listed yet.

Dilek Yazicioglu, Md contact

+905336957855

dilek.yazicioglu@hotmail.com

About this study

Official title: The Prospective Randomized Comparison of the Onset Time of Rocuronium in Patients Undergoing Emergency and Elective Surgery

Rocuronium, a nondepolarizing neuromuscular blocking agent, is used in general anesthesia to provide conditions for endotracheal intubating. Recommended dose is 0,6 mg/kg and 90 seconds after intravenous injection, patients can be intubated.

Anxiety levels may vary in patients undergoing emergency and elective surgery. Patients undergoing emergency surgery may display exaggerated laryngoscopic responses. The purpose of this study is to investigate the effect of patient anxiety levels on the onset time of rocuronium in terms of anxiety scores and train of four (TOF) 0.1 times.

Read the detailed description

After obtaining ethics committee approval, American Society of Anesthesiologists physiological status 1 (ASA 1) patients, undergoing elective inguinal hernia repair and acute appendectomy, will be included to trial.

Patients will be taken to the operating room without premedication. Spielberger's State-Trait Anxiety Inventory (STAI) will be administered to patients for determining anxiety level.

Electrocardiogram, blood pressure and peripheric oxygen saturation (SpO2) will be monitored. After opening intravenous access on hand dorsum, ringer lactate solution will be given. Neuromuscular monitoring and drug injections will be done as described in "Good Clinical Research Practice (GCRP) in pharmacodynamic studies of neuromuscular blocking agents".

TOF-Guard SX acceleromyograph (Organon-Teknika) will be monitored on corrugator supercilii muscle because of its sensitivity to laryngeal muscles. In induction of anesthesia, propofol 2 mg kg-1 and fentanyl 1 mcg kg-1 will be administered intravenously. After loss of conscious, TOF-Guard SX will be calibrated and then 0.6 mg kg-1 rocuronium will be administered in 5 seconds. 20 milliampere (mA) current TOF stimulation (200 ms, square wave, 2 Hz for 1.5 s) will be repeated in every 15 s. Patients will be intubated in TOF 0.1 time.

STAI score, heart rate, systolic blood pressure, diastolic blood pressure, mean arterial pressure, SpO2, TOF 0.1 time and intubation conditions will be compared between two groups.

Being tested
Rocuronium elective surgery, Rocuronium emergency surgery, Propofol, Fentanyl, Ringer Lactate
Keywords
rocuronium, onset time, anxiety
Medical subject headings
Hernia, Inguinal, Appendicitis, Anxiety Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Rocuronium elective surgeryDrug

    Also called esmeron

    Rocuronium onset time in patients undergoing inguinal herniorrhaphy

  • Rocuronium emergency surgeryDrug

    Also called esmeron

    Rocuronium onset time in patients undergoing appendectomy

  • PropofolDrug

  • FentanylDrug

  • Ringer LactateOther

  • Acceleromyography deviceDevice

    Also called TOF Guard Sx

Study groups in NCT02634255
Study groupRoleWhat they receive
Rocuronium elective surgeryActive comparatorpatients undergoing inguinal herniorrhaphy
Receives: Drug: Rocuronium elective surgery; Drug: Propofol; Drug: Fentanyl; Other: Ringer Lactate; Device: Acceleromyography device
Rocuronium emergency surgeryExperimentalpatients undergoing appendectomy
Receives: Drug: Rocuronium emergency surgery; Drug: Propofol; Drug: Fentanyl; Other: Ringer Lactate; Device: Acceleromyography device

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Train of Four Ratio (TOF 0.1)

    Measured: 90 seconds after induction

  2. anxiety score

    Measured: 15 minutes before induction

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Dec 2015 (estimated)
  2. Study startDec 2015
  3. Primary completionMay 2016 (estimated)
  4. Study completionJul 2016 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Participant
Enrolment
50 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02634255
Sponsor's protocol ID
Rocuronium onset
Status last verified
Dec 2015
First submitted
12 Dec 2015
Last updated
18 Dec 2015
Results posted
No
Data monitoring committee
No
Individual data sharing
Undecided

Publications

  • Fuchs-Buder T, Claudius C, Skovgaard LT, Eriksson LI, Mirakhur RK, Viby-Mogensen J; 8th International Neuromuscular Meeting. Good clinical research practice in pharmacodynamic studies of neuromuscular blocking agents II: the Stockholm revision. Acta Anaesthesiol Scand. 2007 Aug;51(7):789-808. doi: 10.1111/j.1399-6576.2007.01352.x.

    PubMed 17635389
  • Kain ZN, Mayes LC, Cicchetti DV, Bagnall AL, Finley JD, Hofstadter MB. The Yale Preoperative Anxiety Scale: how does it compare with a "gold standard"? Anesth Analg. 1997 Oct;85(4):783-8. doi: 10.1097/00000539-199710000-00012.

    PubMed 9322455
  • Plaud B, Debaene B, Donati F. The corrugator supercilii, not the orbicularis oculi, reflects rocuronium neuromuscular blockade at the laryngeal adductor muscles. Anesthesiology. 2001 Jul;95(1):96-101. doi: 10.1097/00000542-200107000-00019.

    PubMed 11465590

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Rocuronium elective surgery, Rocuronium emergency surgery and Propofol in people with Inguinal Hernia and Acute Appendicitis, run by Diskapi Yildirim Beyazit Education and Research Hospital.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 18 Dec 2015. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Gamze Gulgun, Md (+905308705073, dr.gamzegulgun@yahoo.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Train of Four Ratio (TOF 0.1) (time frame: 90 seconds after induction). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02634255, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Dec 2015.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in